Showing 211-220 of 345 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Sequential multi-molecule release from nanofiber scaffolds for improved stem cell-derived islet transplantation under the skin | The Regents of the University of California, San Francisco | Hirotake Komatsu | Cures | 01-March-2024 to 31-July-2026 | $845,444.86 |
| Generation of vascularized, transplantable islets from human iPSC-derived beta and isogenic vasculogenic cells | The Regents of the University of California, San Francisco | Julie Sneddon | Cures | 01-July-2024 to 30-June-2026 | $599,999.99 |
| Designing a safe and effective strategy for T1D cell replacement therapy | The Regents of the University of California, San Francisco | Nur Shabrina Amirruddin | Cures | 01-March-2025 to 29-February-2028 | $264,895.00 |
| Mechanisms of parathyroid protection of transplanted islets | The Regents of the University of California, San Francisco | Peng Xiao | Cures | 01-March-2024 to 28-February-2027 | $228,995.00 |
| Armored SC-beta | The Regents of the University of California, San Francisco | Qizhi Tang | Cures | 01-December-2023 to 28-February-2026 | $499,999.25 |
| Northern California Breakthrough T1D Center of Excellence | The Regents of the University of California, San Francisco | Qizhi Tang | Cures | 01-October-2024 to 30-September-2028 | $7,949,982.98 |
| Pseudohypoxia to improve SC-beta engraftment | The Regents of the University of California, San Francisco | Qizhi Tang | Cures | 01-October-2025 to 30-September-2027 | $600,000.00 |
| Identifying regulators of primary human beta cell survival and proliferation | The Regents of the University of California, San Francisco | Rebecca Lee | Cures | 01-March-2024 to 28-February-2027 | $235,025.00 |
| Engineering Treg Signaling to Develop an Effective Cell Therapy for Type 1 Diabetes | The Regents of the University of California, San Francisco | Roberto Castro-Gutierrez | Cures | 01-March-2026 to 28-February-2029 | $285,000.00 |
| Allogeneic hypoimmunogenic Pancreatic Islets for Treatment of Diabetes in the Intra-Muscular Site | The Regents of the University of California, San Francisco | Tobias Deuse | Cures | 01-August-2024 to 31-July-2026 | $799,998.40 |